Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "annual"

1173 News Found

Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore
News | May 22, 2026

Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore

Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore


India reaffirms commitment to global women and child health agenda at WHA 2026
Policy | May 21, 2026

India reaffirms commitment to global women and child health agenda at WHA 2026

Minister J.P. Nadda holds bilateral meeting with Helen Clark, Board Chair of the Partnership for Maternal, Newborn and Child Health in Geneva


Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%
News | May 20, 2026

Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%

Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance


Lupin gets tentative FDA nod for Revefenacin inhalation solution
Drug Approval | May 20, 2026

Lupin gets tentative FDA nod for Revefenacin inhalation solution

The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)


Manipal Hospital launches ‘Oorja’ Support Group for celiac awareness in children
Hospitals | May 19, 2026

Manipal Hospital launches ‘Oorja’ Support Group for celiac awareness in children

Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease


Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion
Healthcare | May 19, 2026

Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion

Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios


Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge
News | May 19, 2026

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels


Teva study exposes major diagnosis gap in Tardive Dyskinesia
R&D | May 19, 2026

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD


Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%
News | May 18, 2026

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies